Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors

• US 6,545,142 B1
• Filed: 11/28/2000
• Issued: 04/08/2003
• Est. Priority Date: 11/11/1988
• Status: Expired due to Fees

• Current Assignee: UK Research and Innovation
• Original Assignee: Medical Research Council (Government of United Kingdom)
• Inventors: Ward, Elizabeth Sally, Güssow, Detlef, Winter, Gregory Paul
• Primary Examiner(s): KETTER, JAMES S
• Application Number:
  US09/722,364
• Time in Patent Office: 861 Days
• Field of Search: 536/24.33, 536/23.53
• US Class Current: 536/24.33
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/461 Igs containing Ig-regions, -domains or -residues form different species
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C12Q 1/6876 Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.

Claims

1. A primer for introducing mutations into the CDR3-coding sequence of an antibody heavy chain gene, said primer comprising a degenerate sequence of nucleotides for hypermutation of a portion of said CDR3 sequence, flanked by a sequence capable of hybridising to a nucleotide sequence flanking said portion of said CDR3 sequence.

2. The primer of claim 1 which has the sequence as shown as VHMUT1:

5′

- GGAGACGGTG ACCGTGGTCC CTTGGCCCCA GTAGTCAAG NNNNNNNNNN NNCTCTCTGG C 3′

.